




**AI-powered chemistry for drug discovery,
molecular design, and development**

Disclaimer



Forward-Looking Information

This presentation may contain “forward-looking information” within the meaning of applicable Canadian securities legislation (“forward-looking statements”) with respect to Redwood AI Corp. (the “Company”). All information, other than statements of historical facts, included in this presentation that addresses activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations, plans and other such matters, is forward-looking information. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company’s assumptions may not be correct and that actual results may differ materially from those projected in such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “believe”, “will”, “may”, “could”, “plan”, “potential” and similar expressions.

Forward-looking statements contained in this presentation and other forward-looking statements are based on management of the Company’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this presentation, but are not limited to statements with respect to: the Company’s business strategy; future operations, growth, conditions and expected future developments; the timing and completion of corporate transactions; the satisfaction of conditions to closing of offerings, including the receipt, in a timely manner, of regulatory and other required approvals; the terms of the offering; the distribution; the intentions, plans and future actions of the Company; the business and future activities of the Company, including expected developments in the Company’s business and operations; the expected benefits of transactions; future trends and operations; the Company’s business strategy and objectives; management personnel, advisors and consultants; expectations regarding trends in the healthcare industry; the economy generally; the expectations of global pharmaceuticals and chemical manufacturing; contract development and manufacturing organization (“CDMO”) market opportunity; the testing and sales of pharmaceuticals; the use of contract development and manufacturing organizations by biopharma; the growth of the CDMO market; the ability of the Company’s AI model, processes and application; the transformative technology ability of the Company’s AI model; the growth trajectory; and current and continued market position.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Readers are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements based on certain risk factors, which include, but are not limited to: the ability to complete transactions; the ability to achieve the desired synergies or benefits of transactions; the ability to market its products; the market price for the Company’s securities; the volatility and subject to wide fluctuations in response to numerous factors, many of which are beyond the Company’s control; liquidity; regulatory approvals; the Company’s financial position and results of operations may differ materially from expectations; the Company expects to incur future losses and may never generate revenues; the Company may be unable to generate revenues or establish a subscription-based revenue model; the Company may require additional capital to support its business; the Company may be unable to maintain and keep employees; the Company’s market opportunity and success is subject to significant uncertainty; the Company’s intellectual property; cybersecurity and data security breaches; risks associated with operating in a complex healthcare and technology regulatory and legal environment subject to a wide variety of laws and regulations, including those relating to healthcare, consumer products, product liability and consumer protection; regulatory requirements; the ability to maintain effective internal controls; tax laws or interpretation thereof; data protection and privacy laws and regulations; risks associated with research, development or commercialization of products; unfavorable global economic and political conditions could adversely affect the Company’s business, financial condition or results of operations; the Company may not be able to identify or complete acquisitions; and other risks discussed in documents filed by the Company with Canadian securities regulatory authorities, which are available under the Company’s profile on SEDAR+.

The Company and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Unless otherwise specified, all dollar amounts referenced herein are expressed in United States dollars.

Market & Industry Data

This presentation also contains references to certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third-party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

No securities regulatory authority has expressed an opinion about the securities and it is an offence to claim otherwise. An investment in the securities of the Company is speculative and involves a high degree of risk. There are certain risk factors associated with an investment in the Company’s securities and these risk factors should be reviewed carefully and evaluated by readers. Investments in technology, including AI technology, issuers involve a significant degree of risk. An investment in these securities should only be made by persons who can afford the total loss of their investment.



Challenges in Drug Development

Drug discovery, design, and development remain time-intensive, costly, and complex.

- Early-stage drug discovery and molecular design rely on iterative medicinal chemistry processes, limiting efficient exploration of chemical space and constraining downstream candidate advancement.¹
- Chemical synthesis and process development remain highly manual and resource-intensive, contributing to long development timelines and high costs across pharmaceutical research and manufacturing.²
- Drug candidates must simultaneously satisfy multiple criteria including efficacy, safety, pharmacokinetics, manufacturability, and cost, increasing development complexity and reinforcing the need for integrated optimization.¹





Shift Toward AI-Driven Drug Discovery

AI-powered chemistry platforms are reshaping early discovery, molecular design, and development processes.

- AI-driven tools enable broader exploration of chemical space, increasing the number of drug candidates screened and advancing early-stage discovery.¹
- Advances in AI-enabled predictive modeling and optimization of synthesis pathways, improving speed, accuracy, and development efficiency.²
- Integrated AI chemistry platforms are increasingly adopted to support discovery, synthesis planning, and development at scale.³

These trends signal a structural shift toward AI integrated drug discovery and molecular design, laying the foundation for AI-enabled candidate generation.





Redwood AI Overview

Proprietary AI-powered chemistry platform delivering synthesis intelligence across drug discovery and development.

Our Technology

- Redwood AI is building a proprietary AI-powered chemistry platform that integrates advanced chemical analysis with machine learning to predict and optimize synthesis pathways, accelerating drug discovery and molecular design while reducing time, cost, and complexity.
- As the platform scales, it builds a growing proprietary synthesis and reaction dataset derived from real-world deployments, enhancing model performance and creating a competitive advantage that supports future AI-enabled candidate generation and comprehensive pipeline support.

Core Platform

- Redwood's core platform enables scalable exploration of chemical space and optimization of synthesis pathways through integrated AI-driven chemistry analysis, designed for pharmaceutical and biotechnology organizations and broader strategic industries.

Commercialization Strategy

- Redwood aims to commercialize its platform through a subscription-based software-as-a-service model, initially focused on pharmaceutical and biotechnology organizations.
- Each deployment strengthens Redwood's proprietary synthesis and reaction dataset, creating a compounding data advantage over time.

Redwood AI intends to expand toward AI-enabled candidate generation and comprehensive drug pipeline support, leveraging its growing proprietary data foundation.





Existing Technology – Scale and Accuracy



Conventional

Therapeutic drug
for review



AI-Assisted

Manual Process



Drug must be manually
reviewed, with
potentially thousands
of starting materials.

*Multi-week planning
per attempt*

Redwood AI Model Process



Multiple pathways generated.
Less than **1 minute** per pathway.
~**95%** model accuracy.
Abbreviated manual review.

- Manual review cannot be scaled.
- Operational costs for multi-chemist review means either long turnaround times or high project costs.
- Fewer options and contingencies are considered.

- The model is proprietary and uses large language models trained on over 1 billion molecules and 4 million reactions.
- Every step of the synthesis is automatically cost- and vendor-evaluated from 60+ global sources.
- Safety and environmental predictions included.



Platform Evolution

Strategic roadmap for expanding synthesis intelligence into AI-driven drug generation.

Today

- AI-powered synthesis intelligence for pathway prediction and optimization, while capturing structured synthesis and reaction data that supports future candidate generation.

Next

- Deeper integration into discovery and molecular design processes, leveraging accumulated synthesis data to enable faster iteration, improved prioritization, and AI-driven decision support.

Future


- AI-enabled candidate generation and broader drug pipeline support, enabled by expanding synthesis and reaction datasets, including potential proprietary drug candidates.





Positioned Across Intersecting Pharmaceutical Markets

**Global Pharmaceutical Market Size
2020 to 2030 (USD Trillion)**



Source: <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report>

Redwood's AI-powered chemistry platform operates at the intersection of pharmaceutical infrastructure, AI-driven discovery, and next-generation drug creation.

- Embedded within the \$1.65T USD (2024) global pharmaceutical market, projected to exceed ~\$2.35T USD by 2030.¹
- Operates within the \$197.4B+ USD global CDMO market, projected to grow ~\$368.7B USD by 2034.²
- Exposure to the \$6.9B USD (2025) AI-enabled drug discovery market, projected to reach ~\$17.81B USD by 2034.³
- Intends to expand into AI-enabled drug candidate generation and comprehensive drug pipeline support, including potential proprietary candidates.

Source 1: <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report>


Source 2: <https://www.precedenceresearch.com/pharmaceutical-cdmO-market>

Source 3: <https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market>



AI Acceleration in the Global CDMO Market

**Pharmaceutical CDMO Market Size
2025 to 2034 (USD Billion)**



AI adoption in drug manufacturing and development is accelerating, creating a structural opportunity within the global CDMO market.

Market Growth

- The global CDMO market is projected to grow from \$197.4B USD in 2025 to ~\$368.7B USD by 2034.¹

Why This Matters

- CDMOs underpin drug development and commercialization infrastructure.²
- Increasing molecule complexity and biologics demand require more advanced synthesis planning and scalable manufacturing solutions.²
- Redwood's AI-powered chemistry platform integrates directly into this infrastructure, improving speed, cost efficiency, and scalability across the drug lifecycle.

Source 1: <https://www.precedenceresearch.com/pharmaceutical-cdm0-market>


Source 2: <https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/pharma-outsourcing-trends-2025-partnership-precision-and-res/>

Source 3: <https://www.contractpharma.com/exclusives/ai-in-pharma-manufacturing-trends-applications-shortening-timelines/>



AI in Drug Discovery and Molecular Design

**AI In Drug Discovery Market Size, by Application
2025 to 2035 (USD Billion)**



Source: <https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market>

AI adoption is accelerating in early discovery, molecular design, and candidate prioritization.

Market Growth

- The global AI in drug discovery market is projected to grow from \$6.9B USD in 2025 to ~ \$17.81B USD by 2035.¹
- Forecasts consistently show double-digit growth as AI becomes embedded in early-stage discovery and design.¹

Why This Matters

- Early-stage discovery and molecular design are capital-intensive and iterative.
- AI enables broader exploration of chemical space and faster prioritization.
- Platforms that integrate synthesis intelligence with discovery and candidate prioritization are positioned to capture greater value across the drug development lifecycle.



Competitive Landscape - Synthesis

Company	Cost Included?	Synthesis Captured?	Scale Included?	Safety Included?	Environment Review?
Redwood AI, 2026	+	++	+	+	+
IBM RXN	-	+	-	-	-
Iktos Spaya	+	+	-	-	-
Merck Synthia	+	+	-	+/-	+/-
ChemAIRS	-	+	+	+/-	-

Sources: Company websites, product documentation, published literature, and management’s assessment as of February 2026.

+ = native capability, +/- = partial or via companion tool, - = not available



Comparable AI Drug Discovery Platforms

Company	Location	Total Capital Raised (USD)	Notes
 OWKIN	France	\$300M +	AI for drug and diagnostic discovery. Backed by Sanofi and Bristol Myers Squibb.
 Insilico Medicine	USA / Hong Kong	\$400M +	AI driven generative drug discovery platform. AI designed candidates advanced to clinical trials.
Generate :Biomedicines	USA	\$700M +	Generative biology for therapeutic design. Backed by Amgen.
 Recursion.	USA	\$1B +	AI for drug discovery platform. Publicly listed with with major pharma partnerships.

Source: Publicly available financing disclosures, including company press releases, regulatory filings, and third-party databases. Information believed to be accurate as of the dates shown.

Who We Are

- Two successful private company exits and multiple IPOs.
- Experience ranging from chemistry and data science to financing.
- Affiliations with top US and Canadian Universities.
- Public company experience, listings on NASDAQ, CSE, TSX and TSX-V.



Team




Louis Dron, MSc –
CEO



Kristian Thorlund, PhD –
President & Director



Glenn Sammis, PhD –
Head of Chemistry



Ofir Harari, PhD –
Head of AI



Prince Lat, PhD –
Senior Data Scientist



Joey Lai –
Research Scientist


Directors & Officers




Nico Mah –
CFO & Corporate
Secretary



Masoud Darbandi –
Director



Graydon Bensler –
Director



Zachary Stadnyk –
Director



Matthew Mingay –
Director

TEAM



Louis Dron, MSc
CEO

Mr. Dron is a healthcare executive with multidisciplinary experience spanning clinical science, health technology, and leadership roles across corporate and research settings. His background includes clinical diagnostics and leading research teams focused on real-world evidence in healthcare. He began his career at the UK National Health Service, later transitioning into senior research and development leadership roles integrating real-world evidence, biostatistics, and epidemiology into healthcare decision-making. Mr. Dron also serves as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation and is a graduate of the University of Manchester and the University of Leicester.



Kristian Thorlund, PhD
President & Director

Dr. Thorlund, with over 15 years of experience in data science and AI, is an established serial entrepreneur having been involved in the foundation of five Canadian-based businesses, with two successful multi-million dollar exits, over the past decade focused on health technologies. Kristian is an expert in AI and data analysis, ranking within the top 1% of researchers in his field worldwide by citation count. Alongside his business interests, Kristian is a part-time professor at McMaster University, acquiring over \$6 million in grants. He has also held an academic appointment at Stanford University and has collaborated extensively with the Bill & Melinda Gates Foundation. He is a graduate of the University of Copenhagen and McMaster University.



Glenn Sammis, PhD
Head of Chemistry

Dr. Sammis is a worldwide leader in chemistry, acting as an accomplished academic with nearly two decades of experience. Currently, a professor at the University of British Columbia, he has built an exceptional teaching record, excelling across a wide range of courses, student evaluations, course development, creation of innovative materials, and teaching leadership. At his time at UBC, Dr. Sammis has acquired over \$5.5m in grants. Outside of his research group being at the forefront of pioneering advances in radical and photochemical processes, Glenn has acted as an advisor for synthesis problems for over 10 private companies. He is a graduate of Stanford University and Harvard University.



Ofir Harari, PhD
Head of AI

Dr. Harari is a highly experienced statistician and data scientist with over 15 years of experience across various industries, including healthcare, pharmaceuticals, finance and academia. He has a proven track record in both practical data analysis and methodological research, consistently mentoring teams and advancing innovative solutions in healthcare, AI, and statistical science. In recent years, in addition to his tenure at Redwood AI, he served as a Head of Biostatistics at Purpose Life Science and has previously worked for PayPal. He is a graduate of Ben Gurion University and Tel Aviv University.



Prince Lat, PhD
Senior Data Scientist

Dr. Lat is a passionate researcher and data scientist with a decade of experience. His research spans multiple disciplines, including bioinformatics, biophysics, biochemistry, molecular biology, and DNA nanotechnology. He has also worked in biostatistics and data science, applying these tools to extract insights from complex datasets. He is a graduate of IIT Kanpur and Simon Fraser University.

TEAM CONT'



Nico Mah
CFO & Corporate Secretary

Mr. Mah is a Chartered Professional Accountant and has nearly 8 years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023. He holds a Bachelor of Commerce degree, majoring in Accounting, from the University of Calgary and a CPA designation in Alberta, Canada.



Zachary Stadnyk
Director

Mr. Stadnyk is a public company executive with over 15 years of experience across healthcare, wellness, technology, cannabis, and private equity. He has held senior capital markets and leadership roles, including Head of Corporate Finance at The Supreme Cannabis Company, founder of DC Acquisition Corp. (TSXV), Head of Life Sciences at the TSX and TSXV working with more than 140 listed issuers, and Chief Executive Officer of Love Pharma Inc. He holds a Bachelor of Commerce in Entrepreneurial Management from Royal Roads University.



Graydon Bensler
Director

Mr. Bensler is a financial professional and Chartered Financial Analyst with experience advising private businesses and publicly traded companies in Canada and the United States. He has held investor relations and capital markets roles, including at Kin Communications Inc. and Evans & Evans, and has served as a director of publicly listed companies including Qualigen Therapeutics Inc., Onco-Innovations Limited, and Health Logic Interactive Inc. Mr. Bensler holds a Bachelor of Management and Organizational Studies with a specialization in Finance from the University of Western Ontario.



Masoud Darbandi
Director

Mr. Darbandi is a sales strategist with over 30 years of experience leading national distribution and client relations across the professional wellness industry. He has driven growth for established brands including WELLA, AMERICAN CREW, and NIOXIN and brings experience in commercialization, customer engagement, and brand development within complex stakeholder environments.



Matthew Mingay
Director

Mr. Mingay is a Research Data Scientist at Lawrence Berkeley National Laboratory (UC Berkeley) working at the intersection of biotechnology, computer science, and artificial intelligence. He has over ten years of experience in molecular biology and data science and has contributed to peer-reviewed research in areas including cancer genomics and epigenetics.



Redwood AI Highlights

Expanding Market Opportunity

- Embedded within the \$1.65T (2024) global pharmaceutical market, projected to exceed ~\$2.35T by 2030¹
- Operating within the \$197.4B+ (2025) global CDMO infrastructure market²
- Positioned within the \$6.9B (2025) AI-enabled drug discovery market, projected to reach ~\$17.81B by 2034³

Proprietary AI-Powered Technology

AI-powered chemistry platform designed to accelerate drug discovery and molecular design by predicting and optimizing chemical synthesis pathways. Internally benchmarked model performance demonstrates high predictive accuracy across tested datasets, supported by a growing proprietary reaction dataset.

Purpose-Built for AI-Enabled Drug Discovery

Purpose-built platform integrating synthesis intelligence with discovery and molecular design, enabling scalable exploration of chemical space and supporting long-term expansion into AI-enabled candidate generation and potential proprietary asset development.

Broad Applicability Across Scientific Markets

Applicable across pharmaceuticals, biotechnology, and broader chemical sciences, including drug development, synthesis planning, intellectual property assessment, and non-pharmaceutical chemical applications.

Clear Commercialization Strategy

Subscription based SaaS model serving pharmaceutical and biotechnology organizations, with strategic expansion toward AI-enabled candidate generation and comprehensive drug pipeline support, including potential proprietary asset development.

Experienced Leadership Team

Led by a multidisciplinary team with expertise in artificial intelligence, data science, chemistry, and healthcare, supported by academic and industry experience.





Capital Structure

As of Feb 19, 2026

Common Shares Issued & Outstanding:		33,508,750
Warrants:		6,774,300
Issued & Outstanding Fully Diluted:		42,183,050



Contact

Address:

1505 W 2nd Ave, Suite
506 Vancouver, BC,
V6J1H2



investors@redwoodai.com



www.redwoodai.com

